Treatment and survival of XXXX in the north-west of England: a population-based study.

@entity1 @entity981 @entity706 @entity1778 @entity6444
Classification of @entity706 has changed markedly in recent years and advances have been made in therapy. This study investigated the variations in treatment and survival of 1622 @entity1 in a population-based registry. A total of 1009 cases of @entity706 ( @entity706 ) were classified according to the Kiel classification. Pathology review resulted in major diagnostic changes for 24% of cases. Of the @entity706 cases, 39% had not had full staging procedures. Younger @entity1 were more likely to have been treated with multiagent chemotherapy regimens, as were @entity1 with B symptoms. Median survival for @entity706 @entity1 was 12 months for high-grade @entity1 and more than 60 months for low-grade @entity1 . Significant factors affecting the survival of @entity706 @entity1 were performance status, whether treatment had followed a recognised protocol, whether treatment had been carried out at a specialist oncology centre (SOC), grade of disease, stage, gender and age. The same factors had a significant effect on survival of the @entity1778 @entity1 , except for treatment at an SOC, which had a significant favourable effect on survival of @entity981 ( @entity981 ) @entity1 only. Median survival for @entity1 with @entity6444 was 43 months and 7 months for @entity981 @entity1 .
